Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by FarmerBettyon Aug 17, 2022 10:00am
162 Views
Post# 34901822

RE:RE:RE:RE:RE:total liabilities dropped by $8M in H1

RE:RE:RE:RE:RE:total liabilities dropped by $8M in H1The FDA recieves about 1500 IND filings a year. So folks hanging there hats on this i don't think means much. If approved by year end they are going need with no partner more money to go into the clinic. Scope it out to go into the clinic you have to recruit people takes how many months? Then phase 1 results will take how long and don't expect Promis to have any other diagnostic testing than the big guys currently have in the clinic to show that early readouts have a smoking gun. Wishful thinking. So phase 1 results are how far out 1.5-2years. 
What about the ALS and PD programs are they ever get to the clinic? The company says they will be filing IND's in the second half of this year? How is that going to work? Simple big PP's or Partnerships.
<< Previous
Bullboard Posts
Next >>